Current Guidelines for Protecting Health Workers from Occupational Tuberculosis Are Necessary, but Not Sufficient: Towards a Comprehensive Occupational Health Approach.

health system health workers infection prevention and control occupational health tuberculosis

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
03 06 2020
Historique:
received: 29 04 2020
revised: 28 05 2020
accepted: 29 05 2020
entrez: 7 6 2020
pubmed: 7 6 2020
medline: 13 11 2020
Statut: epublish

Résumé

Health workers globally are at elevated occupational risk of tuberculosis infection and disease. While a raft of guidelines have been published over the past 25 years on infection prevention and control (IPC) in healthcare, studies in different settings continue to show inadequate implementation and persistence of risk. The aim of this commentary is to argue, based on the literature and our own research, that a comprehensive occupational health approach is an essential complement to IPC guidelines. Such an approach includes a health system framework focusing on upstream or mediating components, such as a statutory regulation, leadership, an information system, and staff trained in protective disciplines. Within the classical prevention framework, primary prevention needs to be complemented by occupational health services (secondary prevention) and worker's compensation (tertiary prevention). A worker-centric approach recognises the ethical implications of screening health workers, as well as the stigma perceived by those diagnosed with tuberculosis. It also provides for the voiced experience of health workers and their participation in decision-making. We argue that such a comprehensive approach will contribute to both the prevention of occupational tuberculosis and to the ability of a health system to withstand other crises of infectious hazards to its workforce

Identifiants

pubmed: 32503223
pii: ijerph17113957
doi: 10.3390/ijerph17113957
pmc: PMC7313452
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Canadian Institute of Health Research (CIHR)
ID : ROH-115212
Pays : International

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Global Health. 2016 Mar 31;12:10
pubmed: 27036516
S Afr Med J. 2017 May 24;107(6):475-479
pubmed: 28604316
Int J Environ Res Public Health. 2020 Feb 25;17(5):
pubmed: 32106466
BMC Int Health Hum Rights. 2011 Nov 08;11 Suppl 2:S8
pubmed: 22166059
Ann Intern Med. 1995 May 1;122(9):658-63
pubmed: 7702227
Clin Infect Dis. 2016 May 15;62 Suppl 3:S262-7
pubmed: 27118856
Open Forum Infect Dis. 2017 Aug 29;4(3):ofx137
pubmed: 28875155
Ann Glob Health. 2020 Feb 12;86(1):15
pubmed: 32090022
BMC Infect Dis. 2020 Feb 6;20(1):106
pubmed: 32028895
J Clin Tuberc Other Mycobact Dis. 2019 Aug 21;17:100118
pubmed: 31788560
S Afr Med J. 2004 Oct;94(10):846-50
pubmed: 15532762
Public Health. 2016 Feb;131:75-81
pubmed: 26782050
PLoS One. 2017 Dec 6;12(12):e0189140
pubmed: 29211793
Proc Am Thorac Soc. 2011 Jun;8(3):288-93
pubmed: 21653530
Healthc Q. 2005;8 Spec No:32-8
pubmed: 16334069
Int J Tuberc Lung Dis. 2016 Jul;20(7):941-7
pubmed: 27287648
Trop Med Int Health. 2010 Dec;15(12):1407-12
pubmed: 21137105
Bull World Health Organ. 2016 Jun 1;94(6):415-23
pubmed: 27274593
Int J Tuberc Lung Dis. 2007 Jun;11(6):593-605
pubmed: 17519089
MMWR Recomm Rep. 1994 Oct 28;43(RR-13):1-132
pubmed: 8602125
Eur Respir J. 2019 Apr 18;53(4):
pubmed: 30792341
Am J Infect Control. 2018 Mar;46(3):e13-e17
pubmed: 29326003
MMWR Recomm Rep. 2005 Dec 30;54(RR-17):1-141
pubmed: 16382216
Int J Tuberc Lung Dis. 2015 Jun;19(6):647-53
pubmed: 25946353
J Public Health Policy. 2013 Aug;34(3):388-402
pubmed: 23719292
BMC Med Inform Decis Mak. 2012 Aug 06;12:84
pubmed: 22867054
PLoS One. 2014 Dec 15;9(12):e114364
pubmed: 25501847
BMC Public Health. 2011 Apr 25;11:262
pubmed: 21518434
Clin Infect Dis. 2007 Feb 1;44(3):317-23
pubmed: 17205434
Health Policy Plan. 2016 Mar;31(2):239-49
pubmed: 26104821
Int J Infect Dis. 2015 Mar;32:147-51
pubmed: 25809771
Int J Tuberc Lung Dis. 2017 Feb 1;21(2):140-148
pubmed: 28234076
Presse Med. 2017 Mar;46(2 Pt 2):e53-e62
pubmed: 28256382
BMC Infect Dis. 2015 Mar 07;15:117
pubmed: 25887523
Emerg Infect Dis. 2011 Nov;17(11):2035-7
pubmed: 22099091
Health Policy Plan. 2013 Jan;28(1):100-9
pubmed: 22427258
Int J Occup Environ Health. 2005 Jul-Sep;11(3):305-12
pubmed: 16130973
N Engl J Med. 2018 Jul 12;379(2):138-149
pubmed: 29996082
Saf Health Work. 2020 Mar;11(1):10-18
pubmed: 32206369
MEDICC Rev. 2017 Jan;19(1):16-22
pubmed: 28225541
Ann Intern Med. 2010 Oct 19;153(8):516-22
pubmed: 20956708
J Clin Epidemiol. 2013 Jul;66(7):726-35
pubmed: 23570745
Public Health Action. 2019 Mar 21;9(1):11-14
pubmed: 30963037
Occup Med. 1994 Oct-Dec;9(4):723-34
pubmed: 7878497
Occup Med. 1994 Oct-Dec;9(4):659-70
pubmed: 7878493
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):75-80
pubmed: 29025488
BMC Public Health. 2018 May 25;18(1):661
pubmed: 29801449
BMC Med. 2018 Jun 20;16(1):95
pubmed: 29921272
Bull World Health Organ. 2002;80(7):526-31
pubmed: 12163915
Hum Vaccin Immunother. 2016 Nov;12(11):2753-2764
pubmed: 27388449
BMC Health Serv Res. 2016 Aug 08;16(a):359
pubmed: 27503430
BMC Health Serv Res. 2018 Apr 10;18(1):269
pubmed: 29636041

Auteurs

Rodney Ehrlich (R)

Division of Occupational Medicine, School of Public Health and Family Medicine, University of Cape Town, Observatory, Cape Town 8001, South Africa.

Jerry M Spiegel (JM)

School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.

Prince Adu (P)

School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.

Annalee Yassi (A)

School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH